推荐产品
生物来源
mouse
质量水平
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
1E6, monoclonal
种属反应性
human
制造商/商品名称
Chemicon®
技术
ELISA: suitable
immunofluorescence: suitable
western blot: suitable
同位素/亚型
IgG2b
运输
wet ice
特异性
ORF2.1，衣壳蛋白编码区
免疫原
表位：aa 434-457
应用
ELISA
免疫印迹
免疫荧光
最佳稀释度必须由最终用户确定。
免疫印迹
免疫荧光
最佳稀释度必须由最终用户确定。
抗戊型肝炎病毒抗体，aa 434-457，克隆1E6检测戊型肝炎病毒水平，&已发布&验证可用于WB、ELISA&IF。
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
外形
形式：纯化
液体形式，溶于0.02M PB和0.25M NaCl（pH 7.6）中。含0.1%叠氮化钠。
储存及稳定性
自接收之日起，可在2°-8°C下储存长达12个月。
其他说明
浓度：关于批次特定浓度请参见检验报告。
法律信息
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
除非我们的目录或产品随附的其他公司文件中另有说明，否则我们的产品预期仅用于研究用途，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Fabian Z X Lean et al.
The Journal of general virology, 103(11) (2022-11-11)
Ferrets are widely used for experimental modelling of viral infections. However, background disease in ferrets could potentially confound intended experimental interpretation. Here we report the detection of a subclinical infection of ferret hepatitis E virus (FRHEV) within a colony sub-group
Martijn D B van de Garde et al.
Journal of virology, 90(9), 4394-4401 (2016-02-19)
Genotype 3 (gt3) hepatitis E virus (HEV) infections are emerging in Western countries. Immunosuppressed patients are at risk of chronic HEV infection and progressive liver damage, but no adequate model system currently mimics this disease course. Here we explore the
Shaoli Lin et al.
Current protocols in microbiology, 48, 15L-15L (2018-03-08)
Hepatitis E virus (HEV) predominantly causes acute liver disease in humans and is transmitted via the fecal-oral route. HEV infection in pregnant women can result in grave consequences, with up to 30% fatality. The HEV strains infecting humans mainly belong
Yunlong Li et al.
Antiviral research, 184, 104967-104967 (2020-11-03)
Exposure to hepatitis E virus (HEV) bears a high risk of developing chronic infection in immunocompromised patients, including organ transplant recipients and cancer patients. We aim to identify effective anti-HEV therapies through screening and repurposing safe-in-human broad-spectrum antiviral agents. In
Changbo Qu et al.
Archives of virology, 162(10), 2989-2996 (2017-06-18)
Hepatitis E virus (HEV) infection has emerged as a global health issue, but no approved medication is available. The nucleoside analogue 2'-C-methylcytidine (2CMC), a viral polymerase inhibitor, has been shown to inhibit infection with a variety of viruses, including hepatitis
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门